The evidence presented in this review indicates that the gene and gene product have a key neuroendocrine role and that VGF or its derived peptides may act as biomarkers or therapeutic targets in a number of disorders such as obesity, dementia, depression, and pain. Here, VGF is linked to major depressive disorder.